Abstract
Islet cell antibodies (ICA) disappear in most Type I diabetic subjects within months or a few years after diagnosis, possibly reflecting the disappearance of β-cell autoantigen. In a minority of patients, ICA tend to persist indefinitely. The aim of this study was to evaluate whether the persistence of ICA reflects the persistence of functioning β-cell as a source of autoantigen immunization. In 19 longstanding Type I diabetic patients, selected for having (n = 9) detectable ICA (64.4 ± 8.01 JDF units) or not (n = 10) and matched for the duration of the disease (17.1 ± 3.6 vs 19.1 ± 1.5 yr, respectively), C-peptide secretion was evaluated by an i.v. glucagon test. The insulin requirement and metabolic control of patients with ICA were similar to those without detectable ICA. In contrast, patients with ICA were mostly females (p <0.02), older at diagnosis (p <0.02), with a higher prevalence of associated thyroid (p <0.005) and gastric (p <0.05) autoantibodies and autoimmune diseases (p <0.02). No differences were observed between patients with or without ICA in basal (0.2 ± 0.06 vs 0.10 ± 0.58 pg/ml at 0 min, NS) and glucagon-stimulated (0.23 ± 0.07 vs 0.31 ± 0.16 pg/ml at 6 min, NS) C-peptide levels, showing a virtually absent β-cell secretion in the two groups. These findings indicate that: 1) ICA in some Type I diabetic subjects may persist in the absence of a residual C-peptide secretion and therefore independently of the fate of β-cell autoantigen(s); 2) the long-term persistence of ICA identifies Type I diabetic patients as preferentially female, with an older age of onset and with other associated organ-specific autoimmunities; 3) the mechanisms of islet autoimmune response are heterogeneous.
| Original language | English |
|---|---|
| Pages (from-to) | 319-323 |
| Number of pages | 5 |
| Journal | Diabetes, Nutrition and Metabolism - Clinical and Experimental |
| Volume | 4 |
| Issue number | 4 |
| Publication status | Published - 1991 |
Fingerprint
ASJC Scopus subject areas
- Food Science
- Endocrinology
- Medicine (miscellaneous)
- Endocrinology, Diabetes and Metabolism
- Internal Medicine
Cite this
The long-term persistence of islet cell antibodies in Type I diabetic patients is unrelated to residual β-cell function. / Bosi, E.; Andreotti, A. C.; Girardi, A. M.; Bottazzo, G. F.; Pozza, G.
In: Diabetes, Nutrition and Metabolism - Clinical and Experimental, Vol. 4, No. 4, 1991, p. 319-323.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The long-term persistence of islet cell antibodies in Type I diabetic patients is unrelated to residual β-cell function
AU - Bosi, E.
AU - Andreotti, A. C.
AU - Girardi, A. M.
AU - Bottazzo, G. F.
AU - Pozza, G.
PY - 1991
Y1 - 1991
N2 - Islet cell antibodies (ICA) disappear in most Type I diabetic subjects within months or a few years after diagnosis, possibly reflecting the disappearance of β-cell autoantigen. In a minority of patients, ICA tend to persist indefinitely. The aim of this study was to evaluate whether the persistence of ICA reflects the persistence of functioning β-cell as a source of autoantigen immunization. In 19 longstanding Type I diabetic patients, selected for having (n = 9) detectable ICA (64.4 ± 8.01 JDF units) or not (n = 10) and matched for the duration of the disease (17.1 ± 3.6 vs 19.1 ± 1.5 yr, respectively), C-peptide secretion was evaluated by an i.v. glucagon test. The insulin requirement and metabolic control of patients with ICA were similar to those without detectable ICA. In contrast, patients with ICA were mostly females (p <0.02), older at diagnosis (p <0.02), with a higher prevalence of associated thyroid (p <0.005) and gastric (p <0.05) autoantibodies and autoimmune diseases (p <0.02). No differences were observed between patients with or without ICA in basal (0.2 ± 0.06 vs 0.10 ± 0.58 pg/ml at 0 min, NS) and glucagon-stimulated (0.23 ± 0.07 vs 0.31 ± 0.16 pg/ml at 6 min, NS) C-peptide levels, showing a virtually absent β-cell secretion in the two groups. These findings indicate that: 1) ICA in some Type I diabetic subjects may persist in the absence of a residual C-peptide secretion and therefore independently of the fate of β-cell autoantigen(s); 2) the long-term persistence of ICA identifies Type I diabetic patients as preferentially female, with an older age of onset and with other associated organ-specific autoimmunities; 3) the mechanisms of islet autoimmune response are heterogeneous.
AB - Islet cell antibodies (ICA) disappear in most Type I diabetic subjects within months or a few years after diagnosis, possibly reflecting the disappearance of β-cell autoantigen. In a minority of patients, ICA tend to persist indefinitely. The aim of this study was to evaluate whether the persistence of ICA reflects the persistence of functioning β-cell as a source of autoantigen immunization. In 19 longstanding Type I diabetic patients, selected for having (n = 9) detectable ICA (64.4 ± 8.01 JDF units) or not (n = 10) and matched for the duration of the disease (17.1 ± 3.6 vs 19.1 ± 1.5 yr, respectively), C-peptide secretion was evaluated by an i.v. glucagon test. The insulin requirement and metabolic control of patients with ICA were similar to those without detectable ICA. In contrast, patients with ICA were mostly females (p <0.02), older at diagnosis (p <0.02), with a higher prevalence of associated thyroid (p <0.005) and gastric (p <0.05) autoantibodies and autoimmune diseases (p <0.02). No differences were observed between patients with or without ICA in basal (0.2 ± 0.06 vs 0.10 ± 0.58 pg/ml at 0 min, NS) and glucagon-stimulated (0.23 ± 0.07 vs 0.31 ± 0.16 pg/ml at 6 min, NS) C-peptide levels, showing a virtually absent β-cell secretion in the two groups. These findings indicate that: 1) ICA in some Type I diabetic subjects may persist in the absence of a residual C-peptide secretion and therefore independently of the fate of β-cell autoantigen(s); 2) the long-term persistence of ICA identifies Type I diabetic patients as preferentially female, with an older age of onset and with other associated organ-specific autoimmunities; 3) the mechanisms of islet autoimmune response are heterogeneous.
UR - http://www.scopus.com/inward/record.url?scp=0026349639&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026349639&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0026349639
VL - 4
SP - 319
EP - 323
JO - Diabetes, Nutrition and Metabolism - Clinical and Experimental
JF - Diabetes, Nutrition and Metabolism - Clinical and Experimental
SN - 0394-3402
IS - 4
ER -